NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020

Rhea-AI Summary

NGM Biopharmaceuticals, Inc. (NGM) announced that data from its 24-week Phase 2 study of aldafermin in non-alcoholic steatohepatitis (NASH) will be presented at The Digital International Liver Congress 2020 from August 27-29. The presentation includes positive topline results and new analyses. Additionally, several related poster presentations will showcase findings on biomarkers and improvements in non-invasive tests due to aldafermin therapy. This highlights NGM's ongoing commitment to developing transformative therapeutics for liver diseases.

Positive

• Positive topline results from a 24-week Phase 2 study of aldafermin presented at a major conference.
• New analyses from the study will be shared, adding depth to the existing data.
• Multiple poster presentations on aldafermin-related findings demonstrate ongoing research and development efforts.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH) will be featured in an oral plenary presentation at The Digital International Liver Congress (ILC) 2020, which will be held virtually August 27-29, 2020.

Entitled “Positive topline results from a 24-week, placebo-controlled, multicenter, paired liver biopsy study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis,” the late-breaker oral presentation (LBO-01) will be given by Stephen A. Harrison, M.D., Medical Director at Pinnacle Clinical Research, Visiting Professor of Hepatology at University of Oxford, UK and principal investigator of the study, on Saturday, August 29th at 13:00 – 13:15 CEST (7:00 – 7:15 AM ET). The presentation will include detailed findings from the 24-week Phase 2 study as reported by NGM in February 2020, in addition to new analyses from the study.

NGM will also have several aldafermin-related poster presentations at Digital ILC 2020, including:

Poster (THU-200)
Abstract title:  Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Presenting author:  Rohit Loomba, M.D., Professor of Medicine in the Division of Gastroenterology at University of California, San Diego
Date and time:  8/27/2020, 9:15 – 19:30 CEST (3:15 AM – 1:30 PM ET)

Poster (FRI-258)
Abstract title:  Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in nonalcoholic steatohepatitis and primary sclerosing cholangitis patients
Presenting author:  Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research, Visiting Professor of Hepatology at University of Oxford, UK
Date and time:  8/28/2020, 9:30 – 19:30 CEST (3:30 AM – 1:30 PM ET)

Poster (FRI-047)
Abstract title:  The FGF19 analogue aldafermin (NGM282) improves non-invasive tests in patients with nonalcoholic steatohepatitis
Presenting author:  Marno Ryan, MBBS (Hons), M.D., FRACP, Clinical Associate Professor of Medicine, University of Melbourne, Gastroenterologist and Hepatologist, St Vincent’s Hospital, Melbourne
Date and time:  8/28/2020, 9:30 – 19:30 CEST (3:30 AM – 1:30 PM ET)

Poster (FRI-161)
Abstract title:  Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis
Presenting author:  Lei Ling, Ph.D., Director, Clinical Development, NGM Biopharmaceuticals, Inc.
Date and time:  8/28/2020, 9:30 – 19:30 CEST (3:30 AM – 1:30 PM ET)

All presentations will be available to registered Digital ILC 2020 participants at the meeting website:  https://ilc-congress.eu/programme-digital-ilc-2020/. 

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based
on scientific understanding of key biological pathways underlying liver, retinal and metabolic diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Investor Contact: Alex Schwartz ir@ngmbio.com

Media Contact: Liz Melone media@ngmbio.com

FAQ

What were the results of NGM's Phase 2 study on aldafermin (NGM) for NASH?

The Phase 2 study of aldafermin showed positive topline results, which will be presented at The Digital International Liver Congress 2020.

When will NGM present its aldafermin Phase 2 study results?

NGM will present its study results on August 29, 2020, during The Digital International Liver Congress.

What is the significance of the aldafermin study findings for NGM (NGM)?

The findings could support NGM's strategy in developing treatments for NASH, potentially impacting market perceptions and investor confidence.

Are there any upcoming presentations related to aldafermin by NGM?

Yes, NGM will have several poster presentations at The Digital International Liver Congress focusing on aldafermin and its effects on biomarkers.